Compounds > mms350
Page last updated: 2024-11-13

mms350

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID71519611
CHEMBL ID4759709
SCHEMBL ID14880004
MeSH IDM0591604

Synonyms (9)

Synonym
MMS350
SCHEMBL14880004
3,3'-sulfinylbis(methylene)bis(3-methyloxetane)
SWJHSMBPLKNKAV-UHFFFAOYSA-N
1422514-36-0
3,3'-(sulfinylbis(methylene))bis(3-methyloxetane)
STARBLD0002123
CHEMBL4759709
oxetane, 3,3'-[sulfinylbis(methylene)]bis[3-methyl-

Research Excerpts

Overview

MMS350 is a non-toxic, highly water-soluble radiation mitigator. It exhibits radioprotective effects on bone marrow stromal cells.

ExcerptReferenceRelevance
"MMS350 is a non-toxic, highly water-soluble radiation mitigator that exhibits radioprotective effects on bone marrow stromal cells."( Effects of the bifunctional sulfoxide MMS350, a radiation mitigator, on hematopoiesis in long-term bone marrow cultures and on radioresistance of marrow stromal cell lines.
Cao, S; Epperly, MW; Franicola, D; Greenberger, JS; Shields, D; Shinde, A; Sprachman, MM; Wang, H; Wipf, P, )		1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1726133Antifibrotic activity in human primary lung fibroblasts assessed as decrease in alpha-SMA protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726146Antifibrotic activity against TGFbeta1-induced dermal fibrosis in human skin assessed as reduction in fibronectin expression level stimulated with TGFbeta1 for 24 hrs followed by compound treatment at 500 ug/ml measured after 72 hrs by qRT-PCR analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726153Lipophilicity, log P of the compound2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726139Antifibrotic activity against bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as reduction in COL1A2 mRNA level at 2%, po via gavage administered as single dose measured within 5 days by qRT-PCR analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726135Antifibrotic activity in against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in collagen type-1 protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726131Antifibrotic activity in human primary lung fibroblasts assessed as decrease in IGFBP-3 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726132Antifibrotic activity in human primary lung fibroblasts assessed as decrease in CTGF protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726154Solubility of the compound in water2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726136Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in IGFBP-3 protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726138Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in alpha-SMA protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726124Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in fibronectin protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726129Antifibrotic activity in human primary lung fibroblasts assessed as decrease in fibronectin protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726125Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in collagen type-1 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726130Antifibrotic activity in human primary lung fibroblasts assessed as decrease in collagen type-1 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726140Antifibrotic activity against bleomycin-induced C57BL/6J mouse lung fibrosis model at 2%, po via gavage administered as single dose measured after 14 days by hematoxylin and eosin staining based microscopic analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726127Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in CTGF protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726128Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in alpha-SMA protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726134Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in TGFbeta1-induced fibronectin protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726126Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in IGFBP-3 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726145Antifibrotic activity against TGFbeta1-induced dermal fibrosis in human skin assessed as reduction in COL1A1 expression level stimulated with TGFbeta1 for 24 hrs followed by compound treatment at 500 ug/ml measured after 72 hrs by qRT-PCR analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726144Antifibrotic activity against TGFbeta1-induced dermal fibrosis in human skin assessed as reduction in CTGF expression level stimulated with TGFbeta1 for 24 hrs followed by compound treatment at 500 ug/ml measured after 24 hrs by QRT-PCR analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726142Toxicity in bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as body weight loss2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726137Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in CTGF protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726143Toxicity in bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as improvement in mouse survival relative to control2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
AID1726141Antifibrotic activity against bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as reduction in hydroxyproline level in lung at 2%, po via gavage administered as single dose measured on 14 days by hydroxyproline assay2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.25 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index28.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
safrole
Safrole: A member of the BENZODIOXOLES that is a constituent of several VOLATILE OILS, notably SASSAFRAS oil. It is a precursor in the synthesis of the insecticide PIPERONYL BUTOXIDE and the drug N-methyl-3,4-methylenedioxyamphetamine (MDMA).. safrole : A member of the class of benzodioxoles that is 1,3-benzodioxole which is substituted by an allyl group at position 5. It is found in several plants, including black pepper, cinnamon and nutmeg, and is present in several essential oils, notably that of sassafras. It has insecticidal properties and has been used as a topical antiseptic. Although not thought to pose a significant carcinogenic risk to humans, findings of weak carcinogenicity in rats have resulted in the banning of its (previously widespread) use in perfumes and soaps, and as a food additive.		2.0810benzodioxolesflavouring agent;
insecticide;
metabolite;
plant metabolite
sulfoxide
sulfoxide: synergistic insecticide for use with pyrethrum, allethrin, rotenone, ryania, etc.; RN given refers to parent cpd; structure. sulfoxide : An organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).		7.0810benzodioxoles
ConditionIndicatedRelationship StrengthStudiesTrials
Anemia, Fanconi
[description not available]		02.2110
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		07.2110
Fibrosis, Radiation
[description not available]		02.0810
Radiation Pneumonitis
Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.		02.0810